Wonder when we will getting an up date on this meeting ? This PE A1 scan has huge un met need earning potential , over 1 million cases in the USA with annual costs over $10 Billion each year.
PreSubmission meeting is scheduled to take place in November 2020.
ASX Release – 06 October 2020
Resonance Health Ltd. ABN: 96 006 762 492 141 Burswood Road, Burswood, WA 6100, AUSTRALIA Postal: PO Box 71, Burswood, WA, 6100, AUSTRALIA
www.resonancehealth.com T + 61 8 9286 5300
[email protected] R&D Update:
New Pulmonary Embolism AI Solution Developed Further to the Company’s announcement on 17 October 2017 (‘Collaborative Partnership commences to develop new AI diagnostic tools’
, Resonance Health Ltd (ASX: RHT) (“Resonance Health” or “Company”
is pleased to advise that it has developed a new artificial intelligence (“AI”
tool for the automated review of chest computed tomography (“CT”
scans of patients with suspected pulmonary embolism (“PE”
. This new product, named ‘ALERT-PE’, has been produced by the Company’s AI R&D workstream.
Neural network training has been performed using datasets of the lungs provided via the collaboration with Perth Radiological Clinic (“PRC”
, one of Western Australia’s largest radiology practices. The Company advises that it has filed a Pre-Submission to the United States Food & Drug Administration (“ FDA”
to discuss the requirements for a potential future submission for FDA clearance of ALERT-PE. The PreSubmission meeting is scheduled to take place in November 2020.
The Company considers that ALERT-PE is able to perform as an AI-based radiological computer-assisted triage and notification software for PE. It is intended to assist hospital networks and trained radiologists in workflow triage by flagging and communicating suspected PE pathologies, with the user presented with alert notifications for cases that have suspected PE findings. PE is part of the venous thromboembolism (VTE) spectrum, which ranges from asymptomatic deep vein thrombosis (DVT) to fatal PE, and is a blockage of the pulmonary arteries in the lungs caused by blood clots2 .
With at least 650,000 cases occurring annually, PE is the third most common cause of death in hospitalised patients. Autopsy studies have shown that approximately 60% of patients who have died in hospital had PE, with the diagnosis having been missed in up to 70% of the cases3 .
It is estimated that there are 1 million cases of VTE and over 500,000 hospital admissions in the United States, with annual costs exceeding an estimated 10 billion dollars2 . With prompt treatment, medical intervention can be highly effective and it has been shown to greatly reduce the likelihood of death4 . Symptoms and signs of PE are typically non-specific, when the pre-test probability is high (PE likely), imaging becomes the first-line test to confirm the existence of PE. CT Pulmonary Angiogram (“CTPA”
imaging is widely used for this purpose. It is sufficiently sensitive and specific to exclude the diagnosis of PE when it is negative and to confirm it when positive5
